The progress on sensitivity of PARPi and platinum in mCRPC with DNA damage repair gene mutation
10.3760/cma.j.cn112330-20200311-00184
- VernacularTitle:DNA损伤修复基因突变的mCRPC患者对PARPi和铂类药物敏感性的研究进展
- Author:
Zhonghan ZHOU
1
;
Guiming ZHANG
Author Information
1. 青岛大学附属医院泌尿外科，青岛 266003
- Keywords:
Genes;
Metastatic castration resistant prostate cancer;
DNA damage repair;
Poly ADP-ribose polymerase inhibitor;
Platinum;
Prognosis
- From:
Chinese Journal of Urology
2022;43(2):147-151
- CountryChina
- Language:Chinese
-
Abstract:
DNA damage repair (DDR) defects occurred in 8%-16% of metastatic castration resistant prostate cancer (mCRPC). DDR gene mutation was related to poorer prognosis. Patients with DDR gene mutation, especially BRCA1/2 mutation, showed high sensitivity to poly ADP-ribose polymerase inhibitor (PARPi) and platinum.
